Polypropylene developing monofilament as well as preparation method and application thereof

By encapsulating the iodine contrast agent in polypropylene resin and preparing polypropylene developing monofilaments through thermal stretching process, the problem of iodine contrast agent exudation is solved, and long-term retention and safety improvement of the development effect is achieved while maintaining the Fiber strength and processing properties.

CN118979313AInactive Publication Date: 2024-11-19NANTONG UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411041928.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The iodine contrast agent is prone to ooze out during the development process of existing polymer implant materials, resulting in a reduced development effect and a health and safety hazard. The mechanical properties and processability of conventional developing materials are affected.

Method used

The iodine contrast agent is encapsulated in polypropylene resin, and the polypropylene development monofilament is prepared by thermal stretching and heat setting technology of hollow catheter. The iodine contrast agent content is only 5-12%, and it is heat-encapsulated in the fiber center to avoid polymerization. Acrylic blending ensures development and fiber performance.

Benefits of technology

The long-term retention of the development effect is achieved, the toxic risk of iodine contrast agent to the human body is reduced, and the strength and processing performance of the fiber are maintained, avoiding the leakage and toxic side effects of the developer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979313A_ABST
    Figure CN118979313A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medical equipment, in particular to a polypropylene developing monofilament as well as a preparation method and application thereof, and the polypropylene developing monofilament comprises the following components in parts by weight: 5-12 parts of an iodine contrast agent and 88-95 parts of polypropylene resin. According to the invention, a relatively strong developing effect can be realized by adopting a small amount of iodine contrast agent, so that the fiber keeps relatively high strength. The iodine contrast agent is encapsulated in the polypropylene resin, precipitation of the iodine contrast agent is inhibited, the long-acting developing effect of fibers is reserved, and meanwhile toxicity of the iodine contrast agent to the human body is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical equipment, and in particular to a polypropylene developing monofilament and a preparation method and application thereof. Background Art

[0002] Fiber braided materials are widely used as implantable medical materials for tissue repair and regeneration. However, implanted materials may be displaced and twisted due to human body movement, which may cause infection and inflammation. Therefore, positioning and tracking implanted materials not only helps to determine the status and effectiveness of implanted materials, but also can assist doctors in making quick judgments in the event of postoperative infection, thus reducing the pain of patients.

[0003] Conventional polymer implant materials do not have the function of imaging through CT, ultrasound, fluorescence and other technologies. By blending with contrast agents, implantable polymer materials can be given the function of developing. Metallic bismuth, barium compounds and iodine compounds are commonly used medical contrast agents. The mass fraction of fillers required for composite materials based on metal compounds (such as barium sulfate, etc.) to achieve the developing function generally needs to reach more than 20%, which seriously affects the mechanical properties and spinning properties of the composite materials. For composite developing materials based on iodine compounds, the iodine content can reach about 5% to have a good developing effect. The processability and basic mechanical properties of the material are almost unaffected. In addition, iodine contrast agents are widely used in the development of organs and blood vessels, with low toxic side effects. However, there are also problems in directly preparing developing materials by blending iodine contrast agents with polymer resins. On the one hand, iodine contrast agents are dispersed in various parts of the material, and on the other hand, iodine contrast agents are small molecule compounds. Contrast agents near the edge of the material will gradually seep out over time, reducing the developing effect. In addition, the long-term release of contrast agents may also cause iodine poisoning of other organs. Causing serious health and safety hazards. Summary of the invention

[0004] The purpose of the present invention is to solve the shortcomings of the prior art and to propose a polypropylene developing monofilament and a preparation method and application thereof. By encapsulating the iodine contrast agent in the polypropylene resin, the precipitation of the iodine contrast agent is inhibited, which not only retains the long-term developing effect of the fiber, but also reduces the toxicity of the iodine contrast agent to the human body.

[0005] In order to achieve the above object, the present invention adopts the following technical solutions:

[0006] A polypropylene developing monofilament, comprising, by weight:

[0007] Polypropylene resin 88-95 parts;

[0008] 5-12 parts of iodine contrast medium;

[0009] The sum of the weight parts of the polypropylene resin and the iodine contrast agent is 100;

[0010] The iodine contrast agents include but are not limited to iodine lanthanum, ioversol, iotrolan, iopromide, iopamidol, iomeprol, iodopamine, iofafenac, iodixanol, iohexol, iopromide, and diatrizoate.

[0011] Preferably, the polypropylene resin is a medical grade isotactic polypropylene resin with a melting point of 164-170° C. and an isotactic index ≥ 96%.

[0012] Preferably, the diameter of the polypropylene developing monofilament is 0.17-0.3 mm.

[0013] Another object of the present invention is to provide a method for preparing polypropylene developer monofilament, comprising the following steps:

[0014] Step 1: extrude the polypropylene resin through a single screw extruder at an extrusion temperature of 220-260° C., form through an annular die, pull, and cool to obtain a hollow conduit;

[0015] Step 2: dissolving the iodine contrast agent in a suitable solvent, and injecting the iodine contrast agent solution into the hollow catheter, and completely drying at 60-80° C.;

[0016] Step 3: heat-stretch the hollow catheter filled with iodine contrast agent in step 2, and obtain polypropylene developing monofilament through heat setting and winding.

[0017] Preferably, in step 1, the prepared hollow catheter has an outer diameter of 0.7-1 mm, an inner diameter of 0.4-0.7 mm, and a wall thickness of 0.15-0.2 mm.

[0018] Preferably, the solvent is any one of water, methanol, ethanol and diethyl ether.

[0019] Preferably, in step three, the heat stretching is performed at 140° C., and the stretching ratio is 7-12 times.

[0020] Preferably, in step three, the heat setting method is tension-free heat setting at 150°C.

[0021] The present invention also provides an application of the polypropylene developing monofilament obtained by the above-mentioned preparation method in the preparation of medical materials, specifically: the ends of the polypropylene developing monofilament are heat-sealed and then mixed and woven with monofilaments of polypropylene, PET polyester, polyvinylidene fluoride, etc. to obtain a developable implantable medical material.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] 1. The iodine contrast agent used in the present invention is widely used in various CT imaging occasions and has little toxic and side effects on the human body.

[0024] 2. The weight content of iodine contrast agent in the polypropylene developing fiber prepared by the present invention is only 5-12%, and it is not blended with polypropylene. While maintaining the developing effect, it not only retains the strength of the polypropylene monofilament, but also does not affect the post-processing and weaving molding performance of the monofilament.

[0025] 3. In the polypropylene imaging fiber prepared by the present invention, the contrast agent is completely encapsulated in the central cavity of the polypropylene fiber. The contrast agent is completely present at the center point in the cross-sectional direction. Since it is not blended with polypropylene, it is difficult to diffuse from the center to the polypropylene resin and escape into the human body. During long-term use, the imaging function of the fiber does not decay and does not produce any toxic side effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 It is a schematic diagram of CT imaging of the polypropylene developing fiber of the present invention under a covering. DETAILED DESCRIPTION

[0027] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the accompanying drawings, so that those skilled in the art can better understand the advantages and features of the present invention, thereby making a clearer definition of the protection scope of the present invention. The embodiments described in the present invention are only a part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without making creative work are within the scope of protection of the present invention.

[0028] A polypropylene developing monofilament comprises, by weight: 88-95 parts of polypropylene resin; 5-12 parts of iodine contrast agent; and the sum of the weight parts of the polypropylene resin and the iodine contrast agent is 100.

[0029] The polypropylene resin is a medical grade isotactic polypropylene resin with a melting point of 164-170° C. and an isotactic index of ≥96%. The iodine contrast agent includes but is not limited to ioxilan, ioversol, iotrolan, iopromide, iopamidol, iomeprol, iodopamine, iodifenic acid, iodixanol, iohexol, iopromide, and diatrizoate. The diameter of the polypropylene imaging monofilament is 0.17-0.3 mm.

[0030] A method for preparing polypropylene developer monofilament comprises the following steps:

[0031] Step 1: Extruding polypropylene resin with a single screw extruder, forming through an annular die, pulling, and cooling to obtain a hollow catheter. The polypropylene resin is a medical grade isotactic polypropylene resin with a melting point of 164-170°C and an isotactic index of ≥96%. The size of the prepared hollow catheter is 0.7-1mm in outer diameter, 0.4-0.7mm in inner diameter, and 0.15-0.2mm in wall thickness.

[0032] Step 2: Dissolve the iodine contrast agent in a suitable solvent, and inject the iodine contrast agent solution into the hollow catheter, and completely dry it at 60-80° C. The solvent used is any one of water, methanol, ethanol, and ether.

[0033] Step 3: The hollow catheter filled with iodine contrast agent in step 2 is subjected to heat stretching, heat setting and winding to obtain polypropylene developing monofilament. The heat stretching is carried out at 140° C., the stretching multiple is 7-12 times, and the heat setting method is tension-free heat setting at 150° C.

[0034] An application of the polypropylene developing monofilament obtained by the above-mentioned preparation method in the preparation of medical materials is specifically: the ends of the polypropylene developing monofilament are heat-sealed and then mixed and woven with monofilaments of polypropylene, PET polyester, polyvinylidene fluoride, etc. to obtain a developable implantable medical material.

[0035] Embodiment 1:

[0036] Step 1: extrude the polypropylene resin using a single-screw extruder, set the extrusion temperature to 260°C, adjust the size of the annular die, and obtain a hollow catheter with an outer diameter of 1 mm, an inner diameter of 0.6 mm, and a wall thickness of 0.2 mm through extrusion, traction, and cooling.

[0037] Step 2: Dissolve iodoxilan in methanol, pour the methanol solution containing 5 parts by weight of iodoxilan into 95 parts by weight of the hollow catheter, and completely dry it at 80°C.

[0038] Step 3: The hollow catheter filled with the contrast agent iodine in step 2 is heat-stretched at 140° C. with a stretching ratio of 7 times, and is tension-free heat-set at 150° C. and rolled up to obtain a polypropylene developing monofilament with a diameter of 0.3 mm.

[0039] Embodiment 2:

[0040] Step 1: extrude medical polypropylene using a single-screw extruder, set the extrusion temperature to 220°C, adjust the size of the annular die, and obtain a hollow catheter with an outer diameter of 1 mm, an inner diameter of 0.7 mm, and a wall thickness of 0.15 mm through extrusion, traction, and cooling.

[0041] Step 2: Dissolve ioversol in water, pour the aqueous solution containing 12 parts by weight of ioversol into 88 parts by weight of the hollow catheter, and completely dry at 80°C.

[0042] Step 3: The hollow catheter filled with contrast agent ioversol in step 2 is heat-stretched at 140° C. with a stretching ratio of 10 times, and is tension-free heat-set at 150° C. and rolled up to obtain a polypropylene developing monofilament with a diameter of 0.23 mm.

[0043] Embodiment 3:

[0044] Step 1: Medical polypropylene is extruded using a single-screw extruder, the extrusion temperature is set to 260 degrees Celsius, the size of the annular die is adjusted, and a hollow catheter with an outer diameter of 0.7 mm, an inner diameter of 0.4 mm, and a wall thickness of 0.15 mm is obtained through extrusion, traction, and cooling.

[0045] Step 2: Dissolve iodine fenac in ether, pour the ether solution containing 8 parts by weight of iodine fenac into 92 parts by weight of the hollow catheter, and completely dry at 60°C.

[0046] Step 3: The hollow catheter perfused with the contrast agent iodine fenac in step 2 is heat-stretched at 140° C. with a stretching ratio of 12 times, and is tension-free heat-set at 150° C. and rolled up to obtain a polypropylene developing monofilament with a diameter of 0.17 mm.

[0047] Embodiment 4:

[0048] Step 1: Medical polypropylene is extruded using a single-screw extruder, the extrusion temperature is set to 220 degrees Celsius, the size of the annular die is adjusted, and a hollow catheter with an outer diameter of 0.8 mm, an inner diameter of 0.4 mm, and a wall thickness of 0.2 mm is obtained through extrusion, traction, and cooling.

[0049] Step 2: Dissolve iopromide in water, pour the aqueous solution containing 5 weight parts of iopromide into 95 weight parts of the hollow catheter, and completely dry at 80°C.

[0050] Step 3: The hollow catheter perfused with the contrast agent iopromide in step 2 is heat-stretched at 140° C. with a stretching ratio of 12 times, and is tension-free heat-set at 150° C. and rolled up to obtain a polypropylene developing monofilament with a diameter of 0.2 mm.

[0051] In summary, the present invention can achieve a strong development effect with a small amount of iodine contrast agent, so that the fiber retains a high strength. By encapsulating the iodine contrast agent in polypropylene resin, the precipitation of the iodine contrast agent is inhibited, which not only retains the long-term development effect of the fiber, but also reduces the toxicity of the iodine contrast agent to the human body.

[0052] The description and practice disclosed in the present invention are easy to think and understand for ordinary technicians in the technical field, and several improvements and modifications can be made without departing from the principles of the present invention. Therefore, modifications or improvements made without departing from the spirit of the present invention should also be regarded as the protection scope of the present invention.

Claims

1. A polypropylene developing monofilament, characterized in that: The parts by weight include: Polypropylene resin 88-95 parts; 5-12 parts of iodine contrast medium; The sum of the weight parts of the polypropylene resin and the iodine contrast agent is 100; The iodine contrast agents include iodine lanthanum, ioversol, iotrolan, iopromide, iopamidol, iomeprol, iodopamine, iofafenac, iodixanol, iohexol, iopromide or diatrizoate.

2. The polypropylene developing monofilament according to claim 1, characterized in that: The polypropylene resin is a medical-grade isotactic polypropylene resin with a melting point of 164-170° C. and an isotactic index of ≥96%.

3. The polypropylene developing monofilament according to claim 1, characterized in that: The diameter of the polypropylene developing monofilament is 0.17-0.3 mm.

4. A method for preparing a polypropylene developer monofilament according to any one of claims 1 to 3, characterized in that: The following steps are involved: Step 1: extrude the polypropylene resin through a single screw extruder at an extrusion temperature of 220-260° C., form through an annular die, pull, and cool to obtain a hollow conduit; Step 2: dissolving the iodine contrast agent in a suitable solvent, and injecting the iodine contrast agent solution into the hollow catheter, and completely drying at 60-80° C.; Step 3: heat-stretch the hollow catheter filled with iodine contrast agent in step 2, and obtain polypropylene developing monofilament through heat setting and winding.

5. The method for preparing a polypropylene developer monofilament according to claim 4, characterized in that: In step 1, the prepared hollow catheter has an outer diameter of 0.7-1 mm, an inner diameter of 0.4-0.7 mm, and a wall thickness of 0.15-0.2 mm.

6. The method for preparing a polypropylene developer monofilament according to claim 4, characterized in that: In step 2, the solvent is any one of water, methanol, ethanol and ether.

7. The method for preparing a polypropylene developer monofilament according to claim 4, characterized in that: In step three, the heat stretching is performed at 140° C., and the stretching ratio is 7-12 times.

8. The method for preparing polypropylene developer monofilament according to claim 4, characterized in that: In step 3, the heat setting method is tension-free heat setting at 150°C.

9. Use of polypropylene developer monofilament obtained by the preparation method according to any one of claims 4 to 8 in the preparation of medical materials, characterized in that: The end of the polypropylene developing monofilament is heat-sealed and then mixed and woven with polypropylene, PET polyester and polyvinylidene fluoride monofilament to obtain a developable implantable medical material.

Citation Information

Patent Citations

  • Composite biological patch containing barium sulfate and capable of developing and preparation method of composite biological patch

    CN110522954A

  • Developing medical suture for tissue positioning and preparation method thereof

    CN116763975A

  • X-ray contrast catheter

    JP1993021960U

  • Medical polymeric material containing contrast medium

    JP2000336521A

  • Medical devices

    US20040186377A1